Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background/AimsSerotonin receptor (eg, 5-HT 3 ) antagonists are used to treat nausea and vomiting from a variety of causes.Granisetron transdermal system (GTS) is an appealing delivery system for patients with gastroparesis.To assess if GTS improves nausea and vomiting and other gastroparesis symptoms in patients with gastroparesis. MethodsPatients with gastroparesis and symptoms of nausea and vomiting refractory to conventional treatment were treated with GTS.Symptoms of gastroparesis were assessed using a modified Gastroparesis Cardinal Symptom Index (GCSI).Following 2 weeks of treatment, patients were asked to assess their symptoms and indicate their therapeutic response using the Clinical Patient Grading Assessment Scale (CPGAS) reporting if symptoms of nausea and vomiting improved on a scale: 0 = no change to +7 = completely better. ResultsFifty-one patients received GTS by prescription: average age was 40 ± 17 years, 44 female, 11 diabetics, 23 ± 20% retention at 4 hours on gastric emptying scintigraphy.Thirty-nine of the 51 (76%) patients stated improvement with GTS.There was significant improvement in nausea and vomiting as assessed with CPGAS at 2 weeks (2.28 ± 2.53; P < 0.05).Symptoms of nausea and vomiting significantly improved.Other symptoms including postprandial fullness, loss of appetite, upper abdominal pain, and early satiety improved.Side effects reported included redness at the site of the patch in 7 patients, pruritus in 5, and constipation in 5. ConclusionsGTS was moderately effective in reducing nausea and/or vomiting in 76% of gastroparesis patients.In addition to nausea and vomiting, symptoms of postprandial fullness, loss of appetite, upper abdominal pain, and early satiety also improved.(
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738 · cited 2×
“Gastroparesis is a chronic disorder for which patients need long term treatment.(1) Parenthetically, many of the patients studied here were treated for longer periods of time after an initial favorable 2-week response and some had a sustained response to the granisetron patch.”
BackgroundSelf-citationRentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406 · cited 1×
“The patient assessment of gastrointestinal symptoms (PAGI-SYM) questionnaires included the gastroparesis cardinal symptom index (GCSI) scores as well as additional questions concerning abdominal pain, constipation, and diarrhea.(6,7) The GCSI evaluates the severity of nine symptoms over the past 2 weeks using a Likert…”
Method
Cited by
Camilleri, M., & Sanders, K. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.10.028 · Cited by 151
Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis
Ingrosso, M. R., Camilleri, M., Tack, J., Ianiro, G., Black, C. J., & Ford, A. C. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.12.014 · Cited by 53
Pharmacologic treatments for gastroparesis
Camilleri, M., & Jencks, K. J. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100019 · Cited by 14
European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management
Malagelada, C., Keller, J., Sifrim, D., Serra, J., Tack, J., Mulak, A., Stengel, A., Aguilar, A., Drewes, A. M., Josefsson, A., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.12711 · Cited by 8
Metadata
- Authors
- Midani, D., & Parkman, H. P.
- Venue
- Journal of Neurogastroenterology and Motility
- Published
- 2016-10-30
- Volume
- 22
- Issue
- 4
- Pages
- 650-655
- ISSN
- 2093-0879 (ISSN-L)
- 2093-0887
- OpenAlex
- W2468534258
- Cited by
- 64
- References
- 2
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. https://app.cochat.ai/papers/10.5056/jnm15203
- The paper
- Midani, D., & Parkman, H. P. (2016). Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm15203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.